Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
ORIPRO (Orion Laboratories Pty Ltd T/A Perrigo Australia)
Product name
ORIPRO
Date registered
Evaluation commenced
Decision date
Approval time
189 working days (255)
Active ingredients
progesterone
Registration type
EOI
Indication
ORIPRO (pessaries) is now also indicated for prevention of preterm birth in singleton pregnancies at risk due to:
- Shortened cervix (midtrimester sonographic cervix ≤25 mm) and/or
- Where there is a history of spontaneous preterm birth.